Device Authority adopts usage-based pricing to support KeyScaler expansion

Tern plc

Device Authority is moving KeyScaler to a usage-based pricing model, giving customers more flexibility as machine identity requirements expand across connected devices, operational technology and other non-human identities.

The change replaces the need to commit to fixed device volumes in advance. Instead, customers use credits based on the identity operations they perform, including provisioning identities, rotating credentials, enrolling certificates and adding vulnerability or software bill of materials data.

Fixed licensing can create problems when customers cannot accurately predict device volumes. Companies may pay for unused capacity if deployments are delayed or smaller than expected. If deployments grow faster than planned, they may need additional procurement or licensing before extending security controls.

Usage-based pricing reduces that friction. Customers can increase or reduce consumption in line with deployment activity without relying on long-term forecasts.

Device Authority is also making the full KeyScaler capability set available under the new model rather than requiring separate licence commitments for individual functions. This gives customers more freedom to test additional use cases and extend the platform into new parts of their device estate.

A customer could, for example, trial KeyScaler on a new product line or apply additional intelligence to an existing fleet without first renegotiating its licence structure. That may make it easier for Device Authority to expand within existing customer environments where adoption previously depended on additional budget or procurement decisions.

The model may also improve accessibility for organisations with smaller device estates. These customers can face the same security and compliance pressures as larger operators but may be less willing to make substantial upfront licensing commitments.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

CAR-T therapy brings new approach to multiple myeloma treatment

CAR-T therapy is being used in multiple myeloma and is being studied earlier in the treatment pathway, with research focused on improving durability, safety and access.

Tern cuts H1 loss by 60% as portfolio growth and funding strengthen

Tern reduced its first-half loss by 60%, with net asset value improving and further fundraising strengthening the balance sheet. Additional funding has supported Talking Medicines and Device Authority, while continued progress across the portfolio provides further scope for value creation.

AI control of machines creates a new market for device trust

AI is beginning to control physical machines, increasing demand for technology that can verify device identity before those machines are allowed to act.

Peptide drug development expands beyond GLP-1

GLP-1 success is widening interest in peptide drug development, with the next phase focused on proving clinical value across new therapeutic areas.

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Search